Abstract
We retrospectively evaluated 443 breast cancer patients treated with high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) with autologous stem cell support to characterize the cardiac toxicity of this regimen. Patients had stage II-III (n = 243) or stage IV (n = 200) breast cancer. We observed an overall 5.1% incidence of cardiac complications, both clinical and subclinical, in the whole group: 4.9% in stage II-III and 5.5% in stage IV patients. Clinical cardiomyopathy (CMP) was observed in 1.6% of stage II-III patients (1 case of fatal grade 5 toxicity and 3 cases of grade 3 CMP) and in 3.5% of patients with stage IV disease (1 case of grade 4 and 6 cases of grade 3). The incidence of cardiac toxicity did not differ significantly between the groups. Prior radiation therapy to the mediastinum or left chest wall (P = .001) and advanced age (P = .01) were independent predictors of an increased risk of the appearance of this complication. No pharmacodynamic correlation was observed between any of the 3 drugs and cardiac toxicity.
Original language | English (US) |
---|---|
Pages (from-to) | 198-203 |
Number of pages | 6 |
Journal | Biology of Blood and Marrow Transplantation |
Volume | 6 |
Issue number | 2 A |
DOIs | |
State | Published - 2000 |
Keywords
- Bone marrow transplantation
- Breast cancer
- Cardiac toxicity
- Cyclophosphamide
- Stem cell transplant
ASJC Scopus subject areas
- Hematology
- Transplantation